Log in

7784 Anbogen Therapeutics, Inc. TPEX · Taiwan

Anbogen Therapeutics (7784) news

Anbogen Therapeutics, Inc. is a public biotech or pharmaceutical company listed on TPEX under the ticker 7784, recorded under Taiwan. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Anbogen Therapeutics news

We have not published a story on Anbogen Therapeutics yet. When there is news, it will appear here.

Questions about Anbogen Therapeutics

What is the ticker symbol of Anbogen Therapeutics?

Anbogen Therapeutics, Inc. trades under the ticker 7784 on TPEX.

Where is Anbogen Therapeutics listed?

Anbogen Therapeutics, Inc. is listed on TPEX.

Which country or territory is Anbogen Therapeutics listed under?

Our directory records Anbogen Therapeutics, Inc. under Taiwan.

What does Anbogen Therapeutics do?

Our directory classifies Anbogen Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Anbogen Therapeutics?

The ISIN recorded for Anbogen Therapeutics, Inc. is TW0007784001.

Does aibio.space cover Anbogen Therapeutics?

aibio.space lists Anbogen Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Anbogen Therapeutics?

Companies in our directory listed in the same country and business area as Anbogen Therapeutics: Gin Hwa Biotech, Locus Cell Co., LAUNXP BIOMEDICAL CO., LTD., TaiwanJ Pharmaceuticals Co., HeXun Biosciences Co, Shangya Technology Co.

Investor discussion: Anbogen Therapeutics

Members talk about Anbogen Therapeutics (7784). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open TPEX:7784 on TradingView.

Listing details

Anbogen Therapeutics, Inc. is a public biotech or pharmaceutical company listed on TPEX under the ticker 7784, recorded under Taiwan. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Anbogen Therapeutics, Inc.
Ticker
7784
Listing
TPEX
Country or territory
Taiwan
Business scope
Biotechnology
ISIN
TW0007784001
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.